hepatocellular carcinoma
Conditions
Interventions
Observatoional group:Donafenib
Sponsors
Sun Yat-sen memorial hospital Sun Yat-sen university
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Patients with pathologically diagnosed hepatocellular carcinoma or met the clinical diagnosis criteria for primary HCC; 2.Patients evaluated by the investigator cannot accept surgical treatment and plan to use donafenib with or without other treatment; 3.Voluntarily participate in the study and sign an informed consent.
Exclusion criteria
Exclusion criteria: 1. Pathologically confirmed as a mixed type of hepatocellular carcinoma intrahepatic cholangiocarcinoma (HCC-ICC); 2. Individuals who have been confirmed to be allergic to Donafenib Toluenesulfonate and/or its excipients; 3. Patients with known active bleeding; 4. Patients with active gastrointestinal ulcers, intestinal perforation, or intestinal obstruction; 5. Hypertension and liver dysfunction beyond drug control; 6. Pregnant or lactating women; 7. According to the researcher's assessment, there are serious accompanying diseases that pose a threat to the patient's safety or affect the patient's ability to complete the study; 8. There are other reasons why the researchers believe it is not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progress-free survival, PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event, AE;Objective remission rate, ORR;Overall survival, OS;Disease control rate, DCR; | — |
Countries
China
Contacts
Public ContactYajin Chen
Sun Yat-sen memorial hospital Sun Yat-sen university
Outcome results
None listed